2. Metabolic Enzyme/Protease
  3. Renin
  4. KRI-1314

KRI-1314 is an orally active human renin inhibitor with selectivity for primate renin over non-primate renin. KRI-1314 competitively inhibits the binding of recombinant human renin to its substrate, reduces plasma renin activity, lowers blood pressure, and exhibits high stability in tissue homogenates. KRI-1314 is applicable to research on renin-dependent hypertension and hypertension-related studies.

For research use only. We do not sell to patients.

KRI-1314

KRI-1314 Chemical Structure

CAS No. : 128053-53-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

KRI-1314 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

KRI-1314 is an orally active human renin inhibitor with selectivity for primate renin over non-primate renin. KRI-1314 competitively inhibits the binding of recombinant human renin to its substrate, reduces plasma renin activity, lowers blood pressure, and exhibits high stability in tissue homogenates. KRI-1314 is applicable to research on renin-dependent hypertension and hypertension-related studies[1][2][3].

In Vitro

KRI-1314 (30 min) potently and selectively inhibits human plasma renin (IC50 = 1.8 nM) and shows decreasing inhibitory potency against plasma renin from Japanese monkeys, cynomolgus monkeys, rhesus monkeys, dogs, rabbits, guinea pigs, and rats[1].
KRI-1314 competitively inhibits purified human renin with a Ki value of 0.99 nM[1].
KRI-1314 strongly inhibits renin-like activities in kidney, adrenal, heart, lung, and aorta tissues from Japanese monkeys, with IC50 values ranging from 29 nM to 55 nM[1].
KRI-1314 is highly stable in liver, lung, small intestine, and kidney homogenates from Japanese monkeys, retaining full initial concentration after 4 hours of incubation at 37°C[1].
KRI-1314 potently inhibits human renin with an IC50 of 2.4 nM and does not significantly inhibit cathepsin D or chymotrypsin[2].
KRI-1314 competitively inhibits purified recombinant human renin with a Ki of 4.3 nM[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

KRI-1314 Related Antibodies
In Vivo

KRI-1314 (0.025-3 mg/kg; intravenous administration; single bolus injection) induces a dose-dependent decrease in blood pressure, inhibits plasma renin activity, and exerts no effect on heart rate in anesthetized sodium-depleted Japanese monkeys[1].
KRI-1314 (10-30 mg/kg; oral administration; single dose via feeding tube) produces a maximum blood pressure reduction of approximately 20 mmHg, inhibits renin activity in a dose-dependent manner, and has no effect on heart rate; in sodium-depleted Japanese monkeys, its plasma concentration is maintained for at least 7 hours[1].
KRI-1314 (0.1 mL/kg per min; intravenous injection; infused for 10 min) dose-dependently inhibits recombinant human renin-induced hypertension in denervated SHR, with an ED50 of 0.81 mg/kg for intravenous administration[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Japanese monkey (Macaca fuscata) (both sexes, 7 to 11 kg, sodium-depleted hypertension model)[1]
Dosage: 0.025 mg/kg; 0.05 mg/kg; 0.1 mg/kg; 0.25 mg/kg; 0.5 mg/kg; 1 mg/kg; 3 mg/kg
Administration: i.v.; single bolus injection
Result: Produced dose-dependent blood pressure reduction ranging from 2.0 mmHg (0.025 mg/kg) to 17.5 mmHg (3 mg/kg) within 2-6 min post injection.
Reduced PRA by 88.9%-96.9% at peak hypotension for tested iv doses.
Suppressed PRA by 36.3%-81.9% at 30 min post injection alongside full blood pressure recovery.
Caused no obvious alteration to heart rate.
Animal Model: Japanese monkey (Macaca fuscata) (both sexes, 7 to 11 kg, sodium-depleted hypertension model)[1]
Dosage: 3 mg/kg; 10 mg/kg; 30 mg/kg
Administration: p.o.; single administration via feeding tube
Result: Showed negligible impacts on blood pressure and PRA after 3 mg/kg oral dosage.
Produced around 20 mmHg peak blood pressure drop at 3-4 h and time-dependent PRA suppression at 10 mg/kg.
Produced identical ~20 mmHg maximal hypotension at 3-4 h with stronger sustained PRA inhibition at 30 mg/kg.
Caused no remarkable shift in heart rate across all dosages.
Resulted in measurable plasma drug levels over 7 h, with stable concentrations corresponding to 10 and 30 mg/kg doses.
Animal Model: Male SHR (16 weeks old, 300-350 g body weight)[3]
Dosage: 0.1 mL/kg per min
Administration: intravenous injection; infused for 10 min
Result: Dose-dependently inhibited recombinant human renin-induced hypertension in denervated SHR, with an ED50 of 0.81 mg/kg for intravenous administration.
Molecular Weight

689.84

Formula

C38H51N5O7
CAS No.
SMILES

CC(C)OC([C@H](O)[C@H](CC1CCCCC1)NC([C@H](CC2=CN=CN2)NC([C@@H](CC(N3CCOCC3)=O)CC4=CC=CC5=C4C=CC=C5)=O)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

KRI-1314 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

KRI-1314128053-53-2KRI1314KRI 1314Reninhuman reninprimate reninsnorstatinehypertensionrecombinant human reninplasma renin activityJapanese monkeysnon-primate reninsangiotensinogenrenin-dependent hypertensionInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
KRI-1314
Cat. No.:
HY-183978
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.